Infectious Disease Diagnostics Testing Market Size, Share, Growth, and Industry Analysis, By Types (Molecular Diagnostic Test, POC Infectious Disease Diagnostics Test), By Applications Covered (Hospital, Academics Research, Others), Regional Insights and Forecast to 2035

Infectious Disease Diagnostics Testing Market Size

The Global Infectious Disease Diagnostics Testing Market Size is growing steadily due to the increasing number of viral and bacterial infections and the rising focus on early and accurate disease diagnosis. The market was valued at USD 18,382.22 Million in 2025 and grew by about 3.5% to reach USD 19,025.6 Million in 2026. This growth is supported by the wide use of molecular diagnostic tests and rapid testing methods, which account for more than 50% of all diagnostic tests performed. With annual growth remaining above 3%, the market is expected to reach nearly USD 19,691.5 Million by 2027. Increasing investments in public health systems, which represent nearly 15% of healthcare diagnostic spending, along with the expansion of disease screening programs, are expected to support further market growth. As a result, the Global Infectious Disease Diagnostics Testing Market is projected to reach around USD 25,930 Million by 2035, growing at a CAGR of 3.5% from 2026 to 2035.

The US infectious disease diagnostics testing market is expanding rapidly due to increased demand for rapid, accurate testing solutions, particularly in response to rising infectious diseases. Technological advancements and regulatory support drive this growth.

The infectious disease diagnostics testing market plays a pivotal role in identifying and diagnosing various infectious diseases, which has gained significant importance in light of global health crises. The market encompasses diverse testing methods, including molecular diagnostics, immunoassays, and microbiology tests. With growing awareness regarding early disease detection, the demand for efficient diagnostics tools continues to rise. Innovations like point-of-care testing, and automated diagnostic systems, are transforming the landscape. Additionally, the global increase in infectious diseases due to emerging pathogens has fueled the adoption of advanced diagnostics, contributing to the market's expansion.

Infectious Disease Diagnostics Testing Market Trends 

The infectious disease diagnostics testing market is witnessing notable shifts, driven by several factors. One key trend is the rising adoption of molecular diagnostics, including PCR (polymerase chain reaction) tests, which have gained popularity for their accuracy and speed. In fact, the market for molecular diagnostic testing has seen a surge of approximately 25% in recent years, as it offers faster results compared to traditional methods. Another trend includes the integration of automation in diagnostic processes, streamlining testing procedures and improving efficiency. Automated systems can reduce human error, providing more reliable results in less time, contributing to a 15% growth in market share for automated diagnostic tools.

Additionally, there is a noticeable rise in the demand for rapid diagnostic tests (RDTs), particularly in response to the COVID-19 pandemic. This segment alone has grown by more than 30% in the past three years. The demand for home-based testing kits is also on the rise, with approximately 18% of consumers opting for at-home testing solutions due to their convenience. Overall, technological advancements, coupled with increased demand for quicker, more reliable results, are expected to continue reshaping the infectious disease diagnostics testing market.

Infectious Disease Diagnostics Testing Market Dynamics

The infectious disease diagnostics testing market is influenced by various dynamic factors that shape its growth. These dynamics include the increasing prevalence of infectious diseases globally, the rising demand for advanced diagnostic tools, and the growing focus on healthcare infrastructure improvements in emerging economies. As new pathogens continue to emerge and existing diseases evolve, the need for more sophisticated testing solutions has escalated. Additionally, factors like government initiatives aimed at improving healthcare accessibility and advancements in diagnostic technology are driving the market forward. The rise of precision medicine and personalized diagnostics also plays a critical role in creating opportunities for the market's expansion, as it allows for tailored treatment strategies based on diagnostic results.

Drivers of Market Growth 

Technological advancements in diagnostic tools have significantly propelled market growth. With innovations in PCR-based testing, CRISPR technology, and next-generation sequencing (NGS), testing methods have become more precise and faster. This has led to a 22% increase in the adoption of molecular diagnostics globally. Moreover, the increasing demand for home testing kits has accelerated the adoption of rapid diagnostic tests (RDTs), contributing to a 17% surge in demand in the last five years. These advancements are driving the demand for more efficient and accurate diagnostics, thus fueling the market’s expansion.

Market Restraints 

The high cost of advanced diagnostic equipment remains a significant restraint for the infectious disease diagnostics testing market. The upfront costs associated with sophisticated testing machines, including molecular diagnostic platforms, can be prohibitively expensive for smaller healthcare facilities or clinics. This factor has slowed down market penetration in developing regions, where approximately 28% of healthcare providers struggle to afford advanced diagnostic tools. Additionally, maintenance costs and the need for specialized training for healthcare professionals further exacerbate this barrier. These challenges restrict the widespread adoption of high-end diagnostic solutions, limiting the growth of the market in certain areas.

Market Opportunities 

The rise of personalized medicine presents a significant opportunity for the infectious disease diagnostics testing market. As healthcare moves toward more individualized treatment plans, diagnostics play a crucial role in ensuring accuracy in disease detection and treatment. Personalized diagnostics tailored to genetic profiles and disease susceptibility have shown a 20% increase in demand globally. Furthermore, advancements in molecular diagnostics align with this trend, providing more targeted and effective diagnostic solutions. With the growing push for precision medicine, the infectious disease diagnostics market is poised to experience continued growth, driven by a greater need for customized diagnostics.

Market Challenges 

A major challenge facing the infectious disease diagnostics testing market is the rising costs and expenditures related to advanced diagnostic equipment. While the demand for precise and quick diagnostic tests increases, the financial burden of acquiring and maintaining sophisticated diagnostic equipment remains a significant barrier for healthcare providers, especially in developing regions. Approximately 34% of healthcare providers report difficulty in securing the necessary funding to invest in advanced diagnostic platforms. Additionally, ongoing maintenance and training costs continue to escalate, with a 15% annual increase in operational expenses associated with these devices. These high costs create a barrier to entry for smaller hospitals and clinics, limiting their ability to offer advanced diagnostic solutions. Furthermore, the cost of reagents and consumables for molecular diagnostics can be as high as 40% of the total expenditure for each test, adding another layer of financial constraint. The adoption of cutting-edge diagnostic methods, such as CRISPR and next-generation sequencing (NGS), has also been impeded by the high initial investment required, which hinders their widespread use in less developed healthcare systems. Overall, the escalating costs of diagnostic technology pose a substantial challenge to the market, particularly in resource-constrained regions.

Segmentation Analysis 

The infectious disease diagnostics testing market is categorized into various segments based on type, application, and geography. In terms of type, the market is divided into molecular diagnostics, point-of-care (POC) diagnostics, immunodiagnostics, and others. Molecular diagnostics has seen a substantial rise due to advancements in PCR, next-generation sequencing (NGS), and CRISPR-based diagnostics, which offer high accuracy and sensitivity. POC diagnostics, on the other hand, have surged in demand due to their speed and ease of use, particularly in emergency or rural settings where access to full laboratory facilities is limited. The application segments include hospitals, academic and research institutions, diagnostic laboratories, and home care settings. Hospitals remain the largest consumers of diagnostic testing services due to their high patient volume, contributing to over 50% of the market share. Academic research institutions and diagnostic laboratories are also crucial segments, contributing to the ongoing development and adoption of innovative diagnostic technologies. With the increasing focus on personalized medicine and faster detection, the market continues to evolve, providing a wide range of testing solutions tailored to different applications.

By Type

• Molecular Diagnostic Test: Molecular diagnostic tests are one of the most dominant segments in the infectious disease diagnostics testing market, accounting for a substantial market share. The adoption of PCR-based testing, NGS, and CRISPR technology has surged by 25%, driven by their ability to provide fast and accurate results for detecting infectious agents at a molecular level. PCR, in particular, is widely used for detecting viral, bacterial, and fungal infections, and it has seen a 30% increase in usage worldwide due to its precision. Molecular diagnostics can detect pathogens with high sensitivity and specificity, reducing the chances of false positives and false negatives, which makes it indispensable for diagnosing critical infectious diseases such as HIV, tuberculosis, and COVID-19. Another factor driving growth in this segment is the increasing demand for early detection of infectious diseases, which has grown by 18% in the last five years. As healthcare providers and public health systems emphasize faster, more reliable diagnostic solutions, molecular diagnostics is expected to maintain a dominant position in the market.

• POC Infectious Disease Diagnostics Test: Point-of-care (POC) infectious disease diagnostics tests are experiencing a significant rise in demand due to their ability to provide fast and accurate results at the patient’s bedside or in non-hospital settings. This segment has witnessed a growth rate of 22% over the last few years. POC testing is particularly beneficial for areas with limited access to advanced diagnostic laboratories, as it allows for quick diagnosis and prompt treatment, which is critical in managing infectious diseases. Tests like rapid antigen and antibody tests for diseases such as influenza, COVID-19, and malaria have gained widespread popularity, with a 28% increase in their usage. Moreover, the integration of mobile health (mHealth) solutions with POC diagnostics has further enhanced their accessibility and convenience. Approximately 15% of global healthcare settings now use POC tests as their primary diagnostic tool, due to their cost-effectiveness and ease of use. This is particularly true in rural and underserved regions where healthcare infrastructure is lacking. As the healthcare industry continues to focus on improving patient outcomes through rapid diagnostic solutions, the POC diagnostics market is expected to continue to grow at a steady pace.

By Application

• Hospital: Hospitals represent the largest application segment in the infectious disease diagnostics testing market, driven by the high demand for testing in healthcare settings. Hospitals account for approximately 55% of the global market share, and their demand for diagnostic services continues to rise as the prevalence of infectious diseases escalates. The increasing patient population in hospitals, coupled with the need for quick and accurate diagnostic results, drives the demand for sophisticated testing methods. Hospitals utilize a wide range of diagnostic tests, including molecular diagnostics, immunodiagnostics, and POC tests, to accurately diagnose infections such as influenza, tuberculosis, HIV, and COVID-19. The use of PCR-based tests and rapid antigen tests in hospitals has grown by over 30% in the past few years due to their ability to provide timely results that aid in the early treatment of patients. Furthermore, hospitals are increasingly adopting automated diagnostic solutions, which contribute to a more efficient workflow, reducing the time spent on diagnostics by up to 25%. As hospitals continue to handle a significant volume of infectious disease cases, they will remain a dominant force in the market, driving demand for advanced and accurate diagnostic technologies.

Infectious Disease Diagnostics Testing Regional Outlook

The regional outlook of the infectious disease diagnostics testing market reveals substantial growth across various regions, driven by regional healthcare needs and technological advancements. North America dominates the global market due to its advanced healthcare infrastructure and high investment in medical technology. The region’s healthcare system benefits from the widespread adoption of cutting-edge diagnostics technologies, including molecular and POC diagnostics. Europe follows closely, with countries like Germany, France, and the UK investing heavily in the healthcare sector, particularly in diagnostic research. In the Asia-Pacific region, growing economies and increasing healthcare access in countries like China and India are significantly driving market growth. The region’s healthcare infrastructure is improving, leading to a rise in diagnostic testing demand, especially for emerging infectious diseases. Meanwhile, the Middle East and Africa remain the smallest segment, though they are witnessing gradual growth due to international health initiatives and increasing healthcare investment.

North America

North America is the leading region in the infectious disease diagnostics testing market, contributing to over 40% of the global market share. The region’s robust healthcare infrastructure, combined with high healthcare expenditure, supports the widespread adoption of advanced diagnostic technologies. In particular, the United States leads the market, where hospitals and diagnostic laboratories heavily utilize molecular diagnostics, PCR-based tests, and POC tests. Approximately 60% of diagnostic testing is performed in hospitals, with increasing demand for rapid test kits and home-based diagnostic solutions. Additionally, North America’s healthcare policies focus on improving access to diagnostics, resulting in a 22% rise in testing procedures. The region also benefits from significant investments in research and development, driving innovation in diagnostic tools. Furthermore, the ongoing efforts to address public health emergencies, such as the COVID-19 pandemic, have led to an increase in the demand for diagnostic solutions, ensuring the market’s continued dominance in this region.

Europe

Europe holds a substantial share of the infectious disease diagnostics testing market, with countries like Germany, France, and the UK contributing significantly to the region's growth. The region's healthcare systems prioritize early disease detection and prevention, driving the demand for advanced diagnostic technologies. In particular, Germany accounts for over 20% of the European market share, with a focus on molecular diagnostics and PCR testing for various infectious diseases. France and the UK have also seen a surge in the use of POC diagnostic tests, especially in response to the COVID-19 pandemic. The European market is heavily influenced by government policies that aim to improve healthcare access and quality, which has led to a 17% increase in diagnostic testing demand over the past five years. The shift toward personalized medicine and precision diagnostics has been another driving factor in Europe, with an estimated 19% increase in demand for molecular diagnostic tests. The region also boasts a high level of research and development in diagnostic technologies, contributing to an environment of innovation and continuous improvement. As a result, Europe is expected to maintain steady growth in the infectious disease diagnostics testing market, supported by advancements in healthcare infrastructure and technology.

Asia-Pacific 

The Asia-Pacific region is experiencing rapid growth in the infectious disease diagnostics testing market, fueled by increasing healthcare investments and improvements in diagnostic technology. Countries like China and India have witnessed significant developments in their healthcare infrastructure, leading to an 18% rise in demand for diagnostic testing. The region is expected to contribute to over 25% of the global market share. China’s healthcare market is expanding rapidly, with an emphasis on molecular diagnostics and POC testing solutions, which have seen a 20% increase in adoption in recent years. India, with its large population, has been focusing on affordable diagnostic solutions, leading to a 22% increase in the use of rapid diagnostic tests (RDTs). The increasing prevalence of infectious diseases, coupled with a growing awareness of the need for early detection, is driving the market forward. Moreover, as more healthcare facilities adopt advanced testing methods, Asia-Pacific is poised to become a key growth region in the global infectious disease diagnostics testing market.

Middle East & Africa 

The Middle East & Africa (MEA) region is a rapidly developing market for infectious disease diagnostics testing, although it holds a smaller share compared to other regions, accounting for approximately 7% of the global market. However, it is witnessing a steady increase in demand for diagnostic solutions due to growing healthcare investments and international health initiatives. The Middle East is focusing on enhancing its healthcare infrastructure, leading to a 12% growth in diagnostic testing demand. In particular, countries like Saudi Arabia and the United Arab Emirates (UAE) are investing heavily in advanced diagnostics technologies. Saudi Arabia’s healthcare expenditure increased by 18% in the last five years, driving adoption of PCR-based and immunodiagnostic tests. In Africa, demand for infectious disease diagnostics is growing as countries focus on controlling epidemics such as HIV, malaria, and tuberculosis. South Africa is the largest market in the region, contributing to 40% of the market share, driven by government initiatives to improve access to diagnostics and increase testing capacity. Furthermore, the increasing prevalence of infectious diseases, including emerging ones, has accelerated the adoption of diagnostic technologies, resulting in a 14% increase in the adoption of rapid tests. While the region remains underdeveloped compared to others, efforts to improve healthcare access and combat infectious diseases are driving steady growth in the MEA market.

LIST OF KEY Infectious Disease Diagnostics Testing Market COMPANIES PROFILED

• Abbott
• bioMérieux
• Diasorin
• Roche Diagnostic
• Beckman Coulter
• Becton, Dickinson and Company
• Bio-Rad Laboratories
• Cavidi
• Cepheid
• Corgenix
• Diaxonhit
• Eiken Chemical
• EMD Millipore
• Epitope Diagnostic
• EUROIMMUN
• Gold Standard Diagnostics
• Hologic
• Immunetics
• InBios International

Top Two Companies with Highest Market Share

• Abbott – 28%
• bioMérieux – 19%

Investment Analysis and Opportunities 

The infectious disease diagnostics testing market presents promising investment opportunities, especially in regions with improving healthcare infrastructure and increasing diagnostic needs. Over the last five years, investments in molecular diagnostics and point-of-care (POC) solutions have surged by 22%, driven by the demand for faster, more reliable diagnostic tools. The rise of personalized medicine and increasing government funding for healthcare improvements has also opened avenues for investments. Companies focusing on innovations in diagnostic technology, such as PCR-based testing and CRISPR diagnostics, are expected to receive substantial funding, as these methods are poised to capture significant market share. The Middle East and Africa region, although currently smaller in market size, is an emerging hub for investment, particularly as countries seek to improve their healthcare systems and control infectious diseases. In addition, with the growing burden of diseases like tuberculosis, malaria, and HIV, investments in affordable diagnostic solutions are expected to increase by approximately 18%. The Asia-Pacific region is also attracting attention, with investors focusing on India and China, where the demand for diagnostic tools has seen a 20% growth in the last few years. As healthcare access improves and technology evolves, investors are turning toward this high-growth market to capitalize on future demand.

New Products Development

The development of new products in the infectious disease diagnostics testing market is rapidly advancing, with companies focusing on more efficient, accurate, and user-friendly diagnostic solutions. In recent years, there has been a 25% increase in the introduction of rapid diagnostic tests (RDTs) for a variety of infectious diseases, including COVID-19, influenza, and malaria. These tests are now available in formats that provide results within minutes, making them crucial for urgent care settings. Furthermore, there has been a rise in molecular diagnostic platforms that offer higher sensitivity and specificity, with a 19% increase in the number of PCR-based kits launched in the past two years. Companies like Abbott and bioMérieux have developed innovative platforms that integrate automation and data analytics, improving both the speed and accuracy of results. Point-of-care (POC) testing devices have also seen significant advancements, especially in remote and rural areas, with a 15% increase in their adoption. These new products are designed to cater to the increasing demand for accessible, affordable, and rapid diagnostic testing solutions. As the market continues to evolve, further innovations are expected, including developments in CRISPR-based diagnostics and AI-driven diagnostic tools, which will likely shape the future of infectious disease diagnostics.

Five Recent Developments by Manufacturers in Infectious Disease Diagnostics Testing Market (2023 and 2024)

• Abbott launched a new PCR-based test for detecting respiratory infections, increasing test accuracy by 20% compared to previous models.
• bioMérieux introduced an automated molecular diagnostic platform that reduced testing time by 30% for infectious diseases such as tuberculosis and HIV.
• Roche Diagnostics expanded its portfolio with a rapid antigen test for COVID-19, which has been adopted in over 25% more healthcare settings since its release.
• Beckman Coulter rolled out an enhanced immunoassay platform that increased test sensitivity by 18%, improving the detection of infectious agents in blood samples.
• Cepheid launched a new point-of-care diagnostic device for malaria, achieving a 22% reduction in diagnostic time, making it an essential tool in remote regions.

REPORT COVERAGE of Infectious Disease Diagnostics Testing Market 

The report on the infectious disease diagnostics testing market covers a comprehensive analysis of the key factors driving and restraining market growth, along with market segmentation based on type, application, and region. It provides a detailed overview of the molecular diagnostics, point-of-care (POC) testing, immunodiagnostic tests, and other market categories. In-depth insights into the market trends highlight the growing demand for rapid and reliable diagnostic tests, particularly in response to emerging infectious diseases like COVID-19 and malaria. The report also explores the regional market dynamics, offering detailed assessments for North America, Europe, Asia-Pacific, and the Middle East & Africa. In addition, the report includes a thorough analysis of the competitive landscape, profiling key players such as Abbott, bioMérieux, and Roche Diagnostics, along with their market share, product offerings, and recent developments. The investment opportunities and challenges within the market are also discussed, with a focus on technological advancements, new product developments, and regional healthcare improvements. Furthermore, the report provides a forecast of the market's future growth, emphasizing the increasing role of molecular diagnostics and the demand for personalized medicine in infectious disease detection. The report serves as an essential resource for stakeholders seeking to understand the evolving dynamics and opportunities in this high-growth market.